VitalCare Announces FDA Approval Of Infusion Device Used For ICAT Therapy (Medical News Today)
VitalCare Diabetes Treatment Centers, Inc. (NASDAQ: VDTI), a Nevada Corporation, announced the FDA approval (called allowance to market) exists for the infusion devices used by VitalCare for its Intracellular Activation Therapy (iCAT) treatment of Type 1 and Type 2 diabetes.

Akorn-Strides, LLC Announces FDA Approvals for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron ... (Business Wire via Yahoo!7 Finance)
Akorn-Strides, LLC today announced the approvals of two ANDAs for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR)(BSE: 532531).

FDA Approves VYVANSE(TM) (lisdexamfetamine Dimesylate), The First And Only Once-Daily Prodrug Stimulant To Treat ADHD ... (Medical News Today)
Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the global specialty biopharmaceutical company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE(TM) (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.